

Kevser Oksuzoglu^{1,4*}, Ilknur Alsan Cetin², Feyza Sen³, Tunc Ones¹, Reza Maleki¹, Halil Turgut Turoglu¹ and Tanju Yusuf Erdil¹

¹Department of Nuclear Medicine, Marmara University Pendik Training and Research Hospital, Istanbul, Turkey

²Department of Radiation Oncology, Marmara University Pendik Training and Research Hospital, Istanbul, Turkey

³Department of Nuclear Medicine, Uludag University School of Medicine, Bursa, Turkey

⁴Fevzi Çakmak Mahallesi Muhsin Yazıcıoğlu Caddesi No:10, Üst, Kaynarca/Pendik/Istanbul, Turkey

Dates: Received: 15 October, 2016; Accepted: 28 November, 2016; Published: 29 November, 2016

***Corresponding author:** Kevser Oksuzoglu, MD, Department of Nuclear Medicine, Marmara University, Pendik Training and Research Hospital, Istanbul, Turkey, Tel: 00 90 (542)5188021; Fax: 00 90 (216)3968648; E-mail: kevser.koc@hotmail.com

www.peertechz.com

Case Report

PSMA Accumulation in Benign Pleural Thickening

Abstract

Prostate-specific membrane antigen (PSMA) is a specific type II membrane glycoprotein. We present the case of a 72-year-old man with newly diagnosed prostate cancer who had a ⁶⁸Ga-PSMA PET/CT scan for staging. ⁶⁸Ga-PSMA PET/CT images showed moderate uptake in the right hemithorax, corresponding to pleural thickening seen on the CT images. Histopathologic examination revealed the diagnosis of chronic inflammation. It is important to keep in mind other alternative diagnoses such as chronic inflammation when ⁶⁸Ga-PSMA PET/CT identifies uptake at an atypical site.

images (first intercostals space (Figure 1B) and neighbourhood of the 4 and 6 rib (Figure 1C) with normal lung parenchyma. Thoracoscopic biopsy was performed to establish a definitive diagnosis. The results of histopathological examination (excisional biopsy) indicated the features of chronic inflammation with focal mesothelial hyperplasia. There was no evidence of stromal invasion.

Prostate-specific membrane antigen (PSMA) is a specific type II membrane glycoprotein and its expression is suppressed by androgen in prostate cancer. PSMA is a promising target for both therapy with monoclonal antibodies and imaging [1-3].

PSMA is not specific to the epithelium of prostate gland and is expressed in normal other tissues too, for example urinary bladder, proximal tubules of kidney, liver, salivary glands, oesophagus, stomach, small intestine and neuroendocrine cells in the colon. Some malignant lesions such as adrenocortical carcinoma and some benign lesions (schwannomas) can cause abnormal PSMA-ligand uptake that may be confused with metastases [4-6]. Also, PSMA is expressed in non-neoplastic reparative and regenerative neovasculture tissues like endothelial cells in keloids, granulation tissue from heart valves and pleura, and different phases of cycling endometrium [7].

Clinical Image

A 72-Year-Old man with newly diagnosed prostate cancer (PSA:12.47ng/ml, Gleason score:3+3) underwent skeletal scintigraphy before treatment. Suspicious Tc-99m MDP uptake was seen on right hemithorax (Figure 1A). Due to suspicious Tc-99m MDP uptake on right hemithorax on bone scintigraphy, further investigation using ⁶⁸Ga-PSMA PET/CT was suggested. ⁶⁸Ga-PSMA PET/CT revealed increased heterogeneous uptake in the right posterolateral segment of prostate gland compatible with prostate needle biopsy findings (adenocarcinoma). ⁶⁸Ga-PSMA PET/CT images showed non-expected slightly increased uptake (SUVmax:1.6) in the right hemithorax greater than mediastinal blood pool activity (SUVmax:1.2), corresponding to pleural thickening seen on the CT




Figure 1: Suspicious Tc-99m MDP uptake was seen on right hemithorax on bone scintigraphy images and the patient was admitted to ⁶⁸Ga-PSMA PET/CT. Slightly increased uptake, corresponding to pleural thickening seen on the CT images (first intercostals space (Figure 1B) and neighbourhood of the 4 and 6 rib (Figure 1C), was seen in the right hemithorax on Ga-68 PSMA PET/CT images.



Chronic inflammation should be kept in mind when interpreting whole-body ^{68}Ga -PSMA PET/CT images and ^{68}Ga -PSMA avid lesions should be confirmed with tissue biopsy before treatment.

References

1. Ghosh A, Heston WD (2004) Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. *J Cell Biochem* 91: 528–539.
2. Noss KR, Wolfe SA, Grimes SR (2002) Upregulation of prostate specific membrane antigen/folate hydrolase transcription by an enhancer. *Gene* 285: 247–256.
3. Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, et al. (2011) Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate specific membrane antigen. *Proc Natl Acad Sci USA* 108: 9578-9582.
4. Wright GL Jr, Haley C, Beckett ML, Schellhammer PF (1985) Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. *Urol Oncol* 1: 18-28.
5. Wang W, Tavora F, Sharma R, Eisenberger M, Netto GJ (2009) PSMA expression in Schwannoma: a potential clinical mimicker of metastatic prostate carcinoma. *Urol Oncol* 27: 525-528.
6. Crowley MJ, Scognamiglio T, Liu YF, Kleiman DA, Beninato T, et al. (2016) Prostat-Specific Membrane Antigen Is a Potential Antiangiogenic Target in Adrenocortical Carcinoma. *J Clin Endocrinol Metab* 101: 981-987.
7. Gordon IO, Tretiakova MS, Noffsinger AE, Hart J, Reuter VE, et al. (2008) Prostate-specific membrane antigen expression in regeneration and repair. *Mod Pathol* 21: 1421-1427.

Copyright: © 2016 Oksuzoglu K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Citation: Oksuzoglu K, Cetin IA, Sen F, Ones T, Maleki R, et al. (2016) PSMA Accumulation in Benign Pleural Thickening. *Int J Radiol Radiat Oncol* 2(1): 023-024. DOI: <http://dx.doi.org/10.17352/ijro.000016>